Sign In
Buy TLSA
$1.18
-0.180 (-13.24%)
At Close: Jun 03, 2026
NEW YORK, April 22, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies
Tiziana Life Sciences' foralumab study highlighted in Neurology Today
09:09am, Friday, 19'th Apr 2024
Tiziana Life Sciences Ltd (NASDAQ:TLSA) said its study on foralumab, the company's lead candidate, was published in Neurology Today, the esteemed news source of the American Academy of Neurology (AAN)
- Intranasal foralumab attenuated microglial activation in patients with non-active secondary progressive multiple sclerosis and progression independent of relapse (PIRA) - - Data presented in a platf
Tiziana Life Sciences says foralumab shows promise in stabilizing certain types of MS
09:30am, Thursday, 18'th Apr 2024
Tiziana Life Sciences Ltd (NASDAQ:TLSA) unveiled new quantitative PET imaging data on foralumab at the Annual Meeting of the American Academy of Neurology in Denver. The company presented data from it
Oral presentation of study shows intranasal foralumab attenuates microglial activation and disease progression in multiple sclerosis (MS) patients with PIRA as measured by changes in PET scans Oral pr
Tiziana Life Sciences to present new imaging data for lead asset at upcoming neurology conference
09:11am, Thursday, 11'th Apr 2024
Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that it will be presenting new data about its lead clinical asset foralumab at the Annual Meeting of the American Academy of Neurology being held from
NEW YORK, April 11, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA ) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough neuro-immunomodulation th
Tiziana Life Sciences to present positive data for lead drug candidate in Alzheimer's disease
08:27am, Tuesday, 05'th Mar 2024
Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that chairman of its Scientific Advisory Board Dr. Howard Weiner will present positive data on intranasal anti-CD3 monoclonal antibody (mAb) in model
Tiziana Life Sciences reveals positive clinical, PET scan findings for intranasal Foralumab in MS patients
08:31am, Monday, 08'th Jan 2024
Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that positive findings have been seen in a total of six out of eight Intermediate Size Patient Population Expanded Access (EA) patients, which have sh
Tiziana Life Sciences to Present at Biotech Showcase Conference in San Francisco, January 8-10, 2024
09:30am, Friday, 05'th Jan 2024
NEW YORK, Jan. 05, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies,
Tiziana Life Sciences files patent for foralumab combination therapy for obesity-associated inflammation
08:08am, Friday, 05'th Jan 2024
Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that it has filed a new patent application relating to the composition and methods for combining a GLP-1 receptor agonist (ra) and foralumab, its lead
Tiziana Life Sciences doses first patient in mid-stage multiple sclerosis study
08:56am, Tuesday, 19'th Dec 2023
Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that the first patient has been dosed in its Phase 2a study which is comparing two doses of its investigational therapeutic intranasal foralumab and p
Tiziana Life Sciences to Present at the Webull LIVE! with Corporate Connect: Biotech Investment Webinar
07:09am, Monday, 04'th Dec 2023
NEW YORK, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies
Tiziana Life Sciences advances multiple sclerosis research program with enrollment and dosing of patients
08:26am, Thursday, 30'th Nov 2023
Biotechnology firm Tiziana Life Sciences Ltd (NASDAQ:TLSA) said it had successfully enrolled and dosed four new patients with non-active secondary progressive multiple sclerosis (na-SPMS) in the Brigh
Tiziana Life Sciences to Present Recent Clinical Updates at BIO-Europe in Munich, Germany, November 6-8, 2023
07:00am, Wednesday, 01'st Nov 2023
NEW YORK, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies
